ALLMedicine™ Anaplastic Large Cell Lymphoma Center
Research & Reviews 911 results
https://doi.org/10.1097/PRS.0000000000009491
Plastic and Reconstructive Surgery; Wu ZY, Han HH et. al.
Aug 10th, 2022 - An increasing number of reports on breast implant-associated anaplastic large cell lymphoma have recently raised concerns about the potential influence of breast implants on carcinogenicity, particularly implants with a textured surface. We compar...
https://doi.org/10.1097/PAS.0000000000001941
The American Journal of Surgical Pathology; Feldman AL, Oishi N et. al.
Aug 9th, 2022 - Anaplastic large cell lymphoma (ALCL) can be classified genetically based on rearrangements (R) of the ALK, TP63, and/or DUSP22 genes. ALK-R defines a specific entity, ALK-positive ALCL, while DUSP22-R and TP63-R define subgroups of ALK-negative A...
https://clinicaltrials.gov/ct2/show/NCT04639843
Aug 5th, 2022 - Background: T-cell lymphomas (TCLs) are a heterogeneous group of lymphoid malignancies defined by clonal proliferation of post-thymic T lymphocytes. Patients with newly diagnosed TCLs are most commonly treated with a CHOP (cyclophosphamide, doxoru...
https://clinicaltrials.gov/ct2/show/NCT05444712
Aug 4th, 2022 - Peripheral T-cell lymphoma (PTCL) encompasses a broad range of post-thymic (i.e., mature) sub-entities as defined by the 2017 WHO classification. The most common entities are angioimmunoblastic T-cell lymphoma (AITL) and other Tfh-phenotype PTCL o...
https://clinicaltrials.gov/ct2/show/NCT01979536
Aug 3rd, 2022 - PRIMARY OBJECTIVES: I. To determine the tolerability of brentuximab vedotin given in combination with standard chemotherapy (anaplastic large cell lymphoma [ALCL]99) and to determine the tolerability of crizotinib given in combination with chemoth...
Guidelines 6 results
https://doi.org/10.6004/jnccn.2022.0015
Journal of the National Comprehensive Cancer Network : JN... Horwitz SM, Ansell S et. al.
Mar 12th, 2022 - Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by ang...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894347
British Journal of Haematology; Turton P, El-Sharkawi D et. al.
Nov 23rd, 2020 - Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T-cell non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA-ALCL in anyone with breast implants and new breast sy...
https://doi.org/10.1016/j.anndiagpath.2020.151623
Annals of Diagnostic Pathology; Vega F, Amador C et. al.
Sep 19th, 2020 - The diagnosis of T-cell lymphomas is highly challenging and requires an integrated approach in which clinical, morphologic, immunophenotypic and molecular data are incorporated into the diagnosis. Under the auspices of the American Registry of Pat...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106983
Journal of Clinical Oncology : Official Journal of the Am... Jaffe ES, Ashar BS et. al.
Feb 12th, 2020 - To provide guidelines for the accurate pathologic diagnosis of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), the preoperative evaluation of the patient with suspected BIA-ALCL, and the pathologic evaluation of the capsulecto...
https://doi.org/10.1093/asj/sjw259
Aesthetic Surgery Journal; Clemens MW, Horwitz SM
Feb 12th, 2017 - Published case series demonstrate a lack of treatment standardization for breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) with a wide variety of therapeutic strategies being employed at all stages of disease. The National Compr...
Drugs 3 results see all →
Clinicaltrials.gov 78 results
https://clinicaltrials.gov/ct2/show/NCT04639843
Aug 5th, 2022 - Background: T-cell lymphomas (TCLs) are a heterogeneous group of lymphoid malignancies defined by clonal proliferation of post-thymic T lymphocytes. Patients with newly diagnosed TCLs are most commonly treated with a CHOP (cyclophosphamide, doxoru...
https://clinicaltrials.gov/ct2/show/NCT05444712
Aug 4th, 2022 - Peripheral T-cell lymphoma (PTCL) encompasses a broad range of post-thymic (i.e., mature) sub-entities as defined by the 2017 WHO classification. The most common entities are angioimmunoblastic T-cell lymphoma (AITL) and other Tfh-phenotype PTCL o...
https://clinicaltrials.gov/ct2/show/NCT01979536
Aug 3rd, 2022 - PRIMARY OBJECTIVES: I. To determine the tolerability of brentuximab vedotin given in combination with standard chemotherapy (anaplastic large cell lymphoma [ALCL]99) and to determine the tolerability of crizotinib given in combination with chemoth...
https://clinicaltrials.gov/ct2/show/NCT04881838
Jul 26th, 2022 - Anaplastic large cell lymphoma (ALCL) accounts for 15% of pediatric and adolescent non-Hodgkin lymphomas (NHLs). In our historical study (retrospective multicenter study), the 3-year event-free survival (EFS) was 65% for 80 eligible patients treat...
https://clinicaltrials.gov/ct2/show/NCT03397953
Jul 26th, 2022 - Anaplastic large cell lymphoma (ALCL) is a rare non-Hodgkin's lymphoma, around 30% patients would get relapse. Vinorelbine(Navelbine) is a third-line treatment option for Hodgkin's disease(HD) after transplantation failed, while both HD and ALCL e...
News 144 results
https://www.medscape.com/viewarticle/977224
Jul 14th, 2022 - The US Food and Drug Administration (FDA) has approved crizotinib (Xalkori) for the treatment of unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT) in adults and children over...
https://www.onclive.com/view/2021-approvals-expand-access-to-care-for-patients-across-tumor-types
Mar 10th, 2022 - Last year marked the 50th anniversary of the National Cancer Act of 1971, a landmark legislation that committed to funding biomedical research, establishing oncology training programs, and building a nationwide network of cancer treatment centers....
https://www.medscape.com/viewarticle/961710
Oct 27th, 2021 - Takeda Pharmaceuticals is now the latest pharmaceutical company to offer a value-based agreement on one of its new targeted therapies. The rebate offer is for brigatinib (Alunbrig) which is approved for the treatment of adults with anaplastic lymp...
https://www.onclive.com/view/tcell-lymphoma-options-burgeoning-with-ongoing-clinical-trials
Oct 6th, 2021 - Steven Horwitz, MD Though T-cell lymphoma is a more rare hematologic malignancy, researchers are exploring therapies such as brentuximab vedotin (Adcetris) to improve outcomes for these patients. For example, the double-blind, randomized, multic...
https://www.onclive.com/view/dr-jagadeesh-on-unmet-needs-in-aggressive-and-rare-lymphoma-subtypes
Oct 6th, 2021 - Deepa Jagadeesh, MD, associate staff, Department of Hematologic Oncology and Blood Disorders, Lymphoma and Bone Marrow Transplant Programs, Cleveland Clinic, discusses unmet needs in aggressive and rare lymphoma subtypes. Most available therapies...